Bayer AGXSWX:BAYN -5.87%35 3-1 Month Momentum % is -11.32% as of Jul. 09, 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 35/100 and a GF Value™ of CHF24.67 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,028 Drug Manufacturers companies, Bayer AG ranks worse than 57.98% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-09), Bayer AG's 3-1 Month Momentum % is -11.32%.
The industry rank for Bayer AG's 3-1 Month Momentum % or its related term are showing as below:
XSWX:BAYN's 3-1 Month Momentum % is ranked worse than 57.98% of 1028
companies
in the Drug Manufacturers industry
Industry Median: -8.615
vs XSWX:BAYN: -11.32
Bayer AG (XSWX:BAYN) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Bayer AG 3-1 Month Momentum % Related Terms
XSWX:BAYN vs LLY, JNJ, ABBV: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Bayer AG's 3-1 Month Momentum % falls into.
Bayer AG (XSWX:BAYN) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG (XSWX:BAYN) has a 3-1 Month Momentum % of -11.32% as of Jul. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bayer AG and its competitors. According to the industry distribution chart, Bayer AG ranks #596 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 58%.
Is Bayer AG's 3-1 Month Momentum % too high?
Bayer AG's current 3-1 Month Momentum % is -11.32%. Based on the distribution chart, Bayer AG ranks #596 out of 1028 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bayer AG has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's 3-1 Month Momentum % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #596 out of 1028 companies for 3-1 Month Momentum %. This places Bayer AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bayer AG and its competitors. Bayer AG's current 3-1 Month Momentum % is -11.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.67, compared to a current price of CHF45.72 — trading 85.3% above its estimated fair value. The current 3-1 Month Momentum % is -11.32%. Bayer AG's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current 3-1 Month Momentum % is -11.32% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF45.72 is trading 85.3% above its estimated GF Value™ of CHF24.67.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
3-1 Month Momentum %: -11.32%
GF Value™: CHF24.67 vs. price of CHF45.72 (85.3% above fair value)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
35GF Score
Get the complete analysis for XSWX:BAYN
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 